Market›Health Care›Health Care Equipment & Supplies›Health Care Supplies
HAEMONETICS CORP MAS

HAE

$59.93Apr 26, 2021 – Apr 24, 2026
Health CareHealth Care Equipment & SuppliesHealth Care Supplies$2.72B
MVM
-$27.9M
TD Variance
-0.283

Every news event mapped to its market reaction — 81 events, 61 months of data. No predictions, just what happened.

PositiveNegativeNo data· Dot size = magnitude · Scroll to zoom · Drag to pan
Hover to inspect

Want the full written briefing?

The chart shows what moved — the briefing shows why. Sourced, dated, no hot takes.

Subscribe on Substack →

News Events

DateReturnCategorySourceHeadline
2025-11-06+35.8%earningsSeeking AlphaHaemonetics Non-GAAP EPS of $1.27 beats by $0.16, revenue of $327M beats by $15.51M
2025-11-06+35.8%legalSEC EDGARHAE 8-K: 2.02 and (SEC Filing)
2025-11-05+33.9%earningsSeeking AlphaHaemonetics Q2 2026 Earnings Preview
2025-08-07-29.4%earningsSeeking AlphaHaemonetics Non-GAAP EPS of $1.10 beats by $0.08, revenue of $321.39M beats by $16.78M
2025-08-07-29.4%legalSEC EDGARHAE 8-K: 2.02 and (SEC Filing)
2025-08-06-27.6%earningsSeeking AlphaHaemonetics Q1 2026 Earnings Preview
2022-02-08+18.9%legalSEC EDGARHAE 8-K: 2.02 and (SEC Filing)
2025-02-06-16.1%earningsSeeking AlphaHaemonetics' stock slides on revenue miss
2025-02-06-16.1%earningsSeeking AlphaHaemonetics targets 24% to 26% hospital revenue growth with momentum in hemostasis and vascular closure
2025-02-06-16.1%earningsSeeking AlphaHaemonetics Corporation (HAE) Q3 2025 Earnings Call Transcript
2025-02-06-16.1%earningsSeeking AlphaHaemonetics reports mixed Q3 results; updates FY25 outlook
2025-02-06-16.1%legalSEC EDGARHAE 8-K: 2.02 and (SEC Filing)
2024-08-08-12.9%legalSEC EDGARHAE 8-K: 2.02 and (SEC Filing)
2021-11-09-12.4%legalSEC EDGARHAE 8-K: 2.02, 5.02, 7.01 (SEC Filing)
2026-02-05-10.7%earningsSeeking AlphaHaemonetics raises fiscal 2026 guidance as plasma and blood management drive 8%-10% organic growth outlook
2026-02-05-10.7%earningsSeeking AlphaHaemonetics Corporation (HAE) Q3 2026 Earnings Call Transcript
2026-02-05-10.7%earningsSeeking AlphaHaemonetics Corporation 2026 Q3 - Results - Earnings Call Presentation
2026-02-05-10.7%earningsSeeking AlphaHaemonetics GAAP EPS of $0.95 misses by $0.01, revenue of $338.9M beats by $6.18M
2026-02-05-10.7%legalSEC EDGARHAE 8-K: 2.02 and (SEC Filing)
2024-11-07+10.6%legalSEC EDGARHAE 8-K: 2.02 and (SEC Filing)
2025-02-05-9.4%earningsSeeking AlphaHaemonetics Q3 2025 Earnings Preview
2021-05-13-9.2%legalSEC EDGARHAE 8-K: 2.02 and (SEC Filing)
2026-01-13-8.0%newsSeeking AlphaHaemonetics Corporation (HAE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
2023-05-11+7.9%legalSEC EDGARHAE 8-K: 2.02 and (SEC Filing)
2021-08-11+7.8%legalSEC EDGARHAE 8-K: 2.02 and (SEC Filing)
2025-01-14-7.4%legalSEC EDGARHAE 8-K: 8.01 and (SEC Filing)
2022-08-10+6.0%legalSEC EDGARHAE 8-K: 2.02 and (SEC Filing)
2025-05-07+5.8%earningsSeeking AlphaHaemonetics Q4 2025 Earnings Preview
2023-02-07-5.6%legalSEC EDGARHAE 8-K: 2.02 and (SEC Filing)
2025-05-08+5.6%earningsSeeking AlphaHaemonetics Non-GAAP EPS of $1.24 beats by $0.02, revenue of $331M beats by $1.62M
2025-05-08+5.6%legalSEC EDGARHAE 8-K: 2.02, 2.05 (SEC Filing)
2022-05-10+5.3%legalSEC EDGARHAE 8-K: 2.02 and (SEC Filing)
2024-12-03-5.2%legalSEC EDGARHAE 8-K: 8.01 and (SEC Filing)
2024-02-08-4.4%legalSEC EDGARHAE 8-K: 2.02 and (SEC Filing)
2026-04-06+4.3%newsStockStory1 Value Stock on Our Buy List and 2 Facing Headwinds
2025-08-11-4.1%analystSeeking AlphaI'm Recommending Haemonetics Again, But With Caveats (Ratings Upgrade)
2024-03-05+4.1%legalSEC EDGARHAE 8-K: 8.01 and (SEC Filing)
2026-03-23-4.0%newsStockStory3 Small-Cap Stocks That Fall Short
2025-03-03+3.7%newsSeeking AlphaHaemonetics announces executive leadership updates
2025-03-03+3.7%legalSEC EDGARHAE 8-K: 5.02, 7.01 (SEC Filing)
2025-02-07-3.5%analystSeeking AlphaHaemonetics downgraded at Bank of America on revised FY25 outlook
2024-05-29-3.5%legalSEC EDGARHAE 8-K: 1.01, 2.03, 3.02 (SEC Filing)
2025-12-11-3.4%analystSeeking AlphaIntuitive Surgical downgraded as Citi previews 2026 in MedTech
2025-11-07+3.4%newsSeeking AlphaHaemonetics Is Still Undervalued, Even After The Rally
2025-11-07+3.4%earningsSeeking AlphaHaemonetics raises 2026 guidance, projects 7%–10% organic growth ex CSL amid strong plasma and hospital performance
2025-11-07+3.4%earningsSeeking AlphaHaemonetics Corporation (HAE) Q2 2026 Earnings Call Transcript
2023-08-08+3.1%legalSEC EDGARHAE 8-K: 2.02 and (SEC Filing)
2021-05-21-2.7%legalSEC EDGARHAE 8-K: 5.02 (SEC Filing)
2025-08-10-2.6%earningsSeeking AlphaHaemonetics Corporation (HAE) Q1 2026 Earnings Call Transcript
2022-11-07+2.6%legalSEC EDGARHAE 8-K: 2.02 and (SEC Filing)
2025-12-15-2.4%analystSeeking AlphaHaemonetics downgraded at Needham on vascular closure device competition
2022-08-08-2.3%legalSEC EDGARHAE 8-K: 5.02 and 5.07 (SEC Filing)
2022-03-21-2.3%legalSEC EDGARHAE 8-K: 5.02, 7.01 (SEC Filing)
2026-01-09-2.2%M&ASeeking AlphaHaemonetics acquires Vivasure Medical
2026-01-09-2.2%legalSEC EDGARHAE 8-K: 8.01 and (SEC Filing)
2024-05-09+2.1%legalSEC EDGARHAE 8-K: 2.02 and (SEC Filing)
2023-10-10-2.0%legalSEC EDGARHAE 8-K: 1.01, 7.01 (SEC Filing)
2026-02-04+2.0%earningsSeeking AlphaHaemonetics Q3 2026 Earnings Preview
2022-06-16+1.9%legalSEC EDGARHAE 8-K: 5.02 (SEC Filing)
2026-03-30+1.7%legalMT NewswiresHaemonetics Wins FDA Approval to Expand Label for VASCADE MVP XL
2026-03-30+1.7%legalPR NewswireHaemonetics Receives FDA Approval for Expanded Labeling of the VASCADE MVP® XL Venous Vascular Closure System
2023-12-12+1.5%legalSEC EDGARHAE 8-K: 8.01 and (SEC Filing)
2025-01-03-1.3%legalSEC EDGARHAE 8-K: 5.02 (SEC Filing)
2026-03-31-1.3%earningsGuruFocus.comGVS SpA (STU:4YQ) Q4 2025 Earnings Call Highlights: Strong Safety Division Growth Amidst Challenges
2025-02-20+1.1%newsSeeking AlphaHaemonetics: Almost Blood In The Streets
2026-01-11+0.9%analystSeeking AlphaHaemonetics: Re-Rating Complete, Time To Cash In
2024-05-01+0.9%legalSEC EDGARHAE 8-K: 1.01, 1.02, 2.03 (SEC Filing)
2026-04-17+0.8%legalInsider MonkeyMizuho Adjusts Haemonetics Corporation (HAE) Estimates in Sector-Wide Review
2024-04-01-0.6%legalSEC EDGARHAE 8-K: 8.01 and (SEC Filing)
2022-10-19+0.5%legalSEC EDGARHAE 8-K: 5.02 (SEC Filing)
2023-11-02-0.5%legalSEC EDGARHAE 8-K: 2.02 and (SEC Filing)
2022-05-25-0.4%legalSEC EDGARHAE 8-K: 5.02 (SEC Filing)
2026-04-21-0.4%newsInsider MonkeyRiverwater Sustainable Value Strategy Awaits Haemonetics Corporation’s (HAE) Market Validation
2024-09-16+0.4%legalSEC EDGARHAE 8-K: 5.02 (SEC Filing)
2023-08-07-0.3%legalSEC EDGARHAE 8-K: 5.02, 5.07 (SEC Filing)
2025-05-10-0.3%earningsSeeking AlphaHaemonetics Corporation (HAE) Q4 2025 Earnings Call Transcript
2025-11-28+0.2%newsMoomooAn Intrinsic Calculation For Haemonetics Corporation (NYSE:HAE) Suggests It's 21% Undervalued - Moomoo
2022-08-01+0.0%legalSEC EDGARHAE 8-K: 1.01, 1.02, 2.03 (SEC Filing)
2026-04-01-0.0%newsPR NewswireHaemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2026 Results: May 7, 2026
2026-04-01-0.0%newsSimply Wall St.Is It Time To Reassess Haemonetics (HAE) After Prolonged Share Price Weakness
2026-04-24—newsPR NewswireNew Study Highlights Safety and Efficacy Profile of Haemonetics' VASCADE MVP® XL in Large-Bore Venous Access Closure Procedures
tickerdossier.comtickerdossier.substack.com